Modality
mRNA
MOA
WRNi
Target
IL-23
Pathway
Notch
Breast Ca
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
Jan 2023
→ May 2025
Phase 1Current
NCT04682706
1,092 pts·Breast Ca
2023-01→2025-05·Completed
1,092 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-0211mo agoInterim· Breast Ca
2026-11-158mo awayAdCom· Breast Ca
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Complet…
Catalysts
Interim
2025-05-02 · 11mo ago
Breast Ca
AdCom
2026-11-15 · 8mo away
Breast Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04682706 | Phase 1 | Breast Ca | Completed | 1092 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |